Case Reports

Late-onset NPM1 mutation in a MYC-amplified relapsed/refractory acute myeloid leukemia patient treated with gemtuzumab ozogamicin and glasdegib

Department of Internal Medicine V, Heidelberg University Hospital
Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona
Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona
Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona
Department of Internal Medicine V, Heidelberg University Hospital, Germany; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory, Heidelberg
Department of Internal Medicine V, Heidelberg University Hospital, Germany; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center
Department of Internal Medicine V, Heidelberg University Hospital
Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona
Department of Internal Medicine V, Heidelberg University Hospital, Germany; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory, Heidelberg
Haematologica Early view May 30, 2024 https://doi.org/10.3324/haematol.2023.284922